No information is available on the clinical use of sorafenib during breastfeeding. Because sorafenib is 99.5% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is 25 to 48 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during sorafenib therapy and for 2 weeks after the last dose.
关于索拉非尼在母乳喂养期间的临床应用尚无可用信息。由于索拉非尼与血浆蛋白的结合率为99.5%，因此其在乳汁中的含量可能较低。然而，其半衰期为25至48小时，可能会在婴儿体内蓄积。制造商建议在索拉非尼治疗期间及最后一剂后2周内停止母乳喂养。
